Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | CCKBR | P32239 | 9/20 | 0.34 |
| ▸ | AMY2A | P04746 | 8/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30524340 | 0.88 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31614316 | 0.86 | NMBR (0.38) | PTPN1 | |
| SCHEMBL30343346 | 0.86 | PSEN1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30250211 | 0.86 | OPRD1 (0.36) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30524338 | 0.84 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30384193 | 0.84 | ACE (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30863518 | 0.84 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30437554 | 0.83 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL34461946 | 0.80 | REN (0.39) | CCKBROPRD1 | |
| SCHEMBL31002038 | 0.79 | OPRM1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | PTPN1 4662/4885CCKBR 862/4885AMY2A 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.